Goodwin Procter, McDermott Will & Emery, and Mason Hayes & Curran advised LetsGetChecked, while Latham & Watkins and BakerHostetler advised Truepill on the deal. LetsGetChecked, a...
You must be a Standard 1 Year member to access this content.
Milbank advised Viking Holdings Ltd on the offering, Latham & Watkins advised the underwriters and Ropes & Gray advised the selling shareholders. Viking Holdings Ltd (NYSE:...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP is pleased to announce that 34 associates have been elected to the partnership and another 48 associates have been promoted to the...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Mineralys Therapeutics, and Shearman & Sterling advised the underwriters. Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the pricing of its upsized initial public...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented CG Oncology in the transaction. CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Ligand in the transaction, while Weil, Gotshal & Manges represented APAC. Ligand Pharmaceuticals Incorporated has announced the signing of a definitive merger...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Icosavax, Inc. in the transaction. Icosavax, Inc. closed a US$100 million Series B Financing, led by RA Capital Management and joined by...
You must be a Standard 1 Year member to access this content.
